COVID-19: AIIMS Bhopal claims good results in drug trial of Mycobacterium W (Mw)

"So far, three COVID-19 patients have recovered after the clinical trial of Mycobacterium W (Mw) at AIIMS," director of the institute Dr Sarman Singh told .

The trials were being run for the last few days and the results were good, as out of four patients enrolled for the trial, three had fully recovered and discharged, he said.

Singh also informed that soon Favipiravir, a drug used in Japan, will also be used for COVID-19 treatment here.

If Mycobacterium W proves effective during the clinical trial, it will be used in the treatment of COVID-19, he said.

Mycobacterium W was used in the treatment of leprosy and recently, the Council for Scientific and Industrial Research (CSIR) has tied up with Cadila Pharmaceuticals Ltd to evaluate the effect of this medicine for faster recovery of hospitalised COVID-19 patients, Singh said.

Drug Controller of India has granted permission to conduct tests on critically ill COVID-19 patients at three major hospitals in the country including AIIMS Bhopal. 

Read Also:  Union Health Ministry designates 14 health establishments to review proposals for COVID 19 testing labs